MEDIA ADVISORY: Metabolife Renews its Call for Strong FDA Regulation of Ephedra

MEDIA ADVISORY

ATTENTION HEALTH AND MEDICAL REPORTERS

A Medical News Special Report

METABOLIFE RENEWS ITS CALL FOR STRONG FDA REGULATION OF EPHEDRA

COMPANY TELLS SENATE GOVERNMENT AFFAIRS SUBCOMMITTEE

THAT METABOLIFE 356 IS SAFE AND EFFECTIVE WHEN USED AS DIRECTED

WHO: SENATE GOVERNMENTAL AFFAIRS COMMITTEE, Oversight of Government Management, Restructuring and the District of Columbia Subcommittee

WHAT: EPHEDRA OVERSIGHT HEARING

WHEN: TUESDAY, OCTOBER 8, 2002

WHY: OBESITY HAS REACHED EPIDEMIC PROPORTIONS. MORE THAN 25% OF ADULTS ARE OVERWEIGHT AND OBESE. BEING OVERWEIGHT AND OBSE ARE MAJOR HEALTH RISKS TO AMERICANS.

THE APRIL 25, 2002 EDITION OF PRESTIGIOUS INTERNATIONAL JOURNAL OF OBESITY, PUBLISHED A LONG-TERM CLINICAL TRIAL OF EPHEDRA CONDUCTED BY RESEARCHERS AT COLUMBIA UNIVERSITY AND HARVARD MEDICAL SCHOOL. THE RESEARCHERS CONCLUDED THAT “HERBAL EPHEDRA/CAFFEINE PROMOTED BODY WEIGHT AND BODY FAT REJECTION AND IMPROVED BLOOD LIPIDS WITHOUT SIGNIFICANT ADVERSE EVENTS.”

EXPERTS AGREE THAT SIGNIFICANT HEALTH BENEFITS MAY BE OBTAINED BY A 5-10% WEIGHT LOSS. METABOLIFE 356 IS SAFE AND EFFECTIVE WHEN USED AS DIRECTED.

METABOLIFE WOULD WELCOME THE OPPORTUNITY TO DISCUSS THIS ISSUE WITH YOU. FOR MORE INFORMATION AND INTERVIEWS CONTACT JAN STRODE, 619.890.4040

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish